GOG 240

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Pubmed             Free PMC article

Hypothesis: Addition of Bevacizumab improves overall survival

Site: Cervix

Experimental arm: Cisplatin (50mg/mg/m2) plus paclitaxel (135 or 175 mg/m2)
OR Topotecan (0.75 mg/m2 days 1,2,3) plus paclitaxel (175 mg/m2)

Standard Arm:Cisplatin (50mg/mg/m2) plus paclitaxel (135 or 175 mg/m2) Bevacizumab
OR Topotecan (0.75 mg/m2 days 1,2,3) plus paclitaxel (175 mg/m2) Bevacizumab

Primary Outcome: Overall Survival

Results:

Outcome Cis/Taxol OR Cis/Topo Cis/Taxol/Bev Or Cis/Topo/Bev p-value
Overall Survival (mths) 13.3 17 SS
Fatal adverse event % 1.8 1.8 NS
G3 fistula % 1 6 SS
G2 or higher HTN 2 25 SS
Febrile neutropenia % 5 5 NS
Thromboembolism % 1 8 SS

Conclusions: Adding Bevacizumab significantly improves OS in cervical cancer


Author: Shitanshu Uppal

Assistant Professor Gynecologic Oncology University of Michigan, Ann Arbor

This site uses Akismet to reduce spam. Learn how your comment data is processed.